-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V8BmIG0Cbdsler7AcYid8UMn2dcTb6Nm+MWxSf0VB59OrZPCK9mnZzwauCL2+6Cc l3RRCm4HQSDv+9nmgJm/mA== 0001144204-04-021531.txt : 20041213 0001144204-04-021531.hdr.sgml : 20041213 20041213153201 ACCESSION NUMBER: 0001144204-04-021531 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041209 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20041213 DATE AS OF CHANGE: 20041213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 041198702 BUSINESS ADDRESS: STREET 1: 6725 MESA RIDGE ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92131 BUSINESS PHONE: 8585520866 MAIL ADDRESS: STREET 1: 6725 MESA RIDGE ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92131 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 8-K 1 v09829form8k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K


CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported) December 9, 2004

ADVENTRX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)


001-32157
(Commission File Number)
  
84-1318182
(IRS Employer Identification No.)


6725 Mesa Ridge Road, Suite 100
San Diego, California 92121
(Address of principal executive offices) (Zip Code)


(858) 552-0866
(Company’s telephone number, including area code)


 
     
 


Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(b) Effective December 9, 2004, Steven M. Plumb was removed by the Board of Directors of the Company from his position as Chief Financial Officer of the Company (principal financial officer).
 
(c) Effective December 9, 2004, Carrie E. Carlander has been appointed by the Board of Directors of the Company to serve as Chief Financial Officer (principal financial officer), Vice President, Finance, and Treasurer of the Company.
 
From August 2004 to December 2004, Ms. Carlander served as Chief Financial Officer of Singlefin, Inc., an email/internet security software company. From December 2003 to December 2004, Ms. Carlander served as Chief Financial Officer of SofLinx, Inc. a wireless sensor network and software company. From December 2002 to June 2004, Ms. Carlander served as Vice President of Finance of V-Enable, Inc. a software company specializing in software that more easily permits multimodal use of wireless devices. From December 1996 to May 2000, Ms. Carlander served first as Director of Finance and Human Resources, and then as Vice President, Finance and Administration, of Websense Inc., a publicly-traded company that provides software products that analyze, report and manage computing resource use by employees.
 
Ms. Carlander has no family relationships with any director or executive officer of the Company or any person nominated or chosen by the Company to become an officer or director of the Company.
 
Ms. Carlander has not entered into any transaction to which the Company was or is a party and no such transaction has been proposed in the past or is currently proposed.
 
Item 8.01. Other Events.

On December 13, 2004, the Company announced the appointment of Carrie E. Carlander to the positions of Chief Financial Officer, Vice President, Finance, and Treasurer of the Company and Brian M. Culley to the position of Vice President, Business Development and the removal of Steven M. Plumb as Chief Financial Officer of the Company. The press release issued by the Company on December 13, 2004 with respect to these appointments is included with this report as an exhibit.

Item 9.01. Financial Statements and Exhibits.
 
(c)            The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.


     
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  ADVENTRX Pharmaceuticals, Inc.
 
 		  
 		  
 
By:   /s/ Carrie E. Carlander
 
Name: Carrie E. Carlander
  Title: Chief Financial Officer, Vice President, Finance, and Treasurer 
   
             December 9, 2004



 
     



EXHIBIT INDEX

Exhibit
Description
 
99.1
 
  
 
Press Release of the Company dated December 13, 2004.
 

 EX-99.1 2 v09829ex-99_1.htm

For immediate release

ADVENTRX Pharmaceuticals Announces Senior Management
Appointments

SAN DIEGO, December 13, 2004 -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today two new senior management appointments. Effective December 9, 2004, Carrie Carlander was named Chief Financial Officer and Brian M. Culley was added as Vice President of Business Development, a newly created position at the Company. Ms. Carlander will replace Steven Plumb in the position of Chief Financial Officer.

"We are pleased to add Carrie and Brian to our team. Both bring valuable strengths and extensive experience to help lead our Company,” said Evan M. Levine, President & CEO of ADVENTRX. “Carrie brings 13 years experience in finance, strategic operations, accounting and management in high tech environments. “Brian has over 12 years experience in the biotechnology industry and business development which we expect will have an immediate impact as we advance our products through clinical development and seek to negotiate strategic licensing arrangements. I consider the addition of these two professionals to our senior management team to be a real win for the Company and its shareholders.

Most recently, Ms. Carlander held consulting CFO positions with SofLinx and Singlefin and was Vice President of Finance at V-Enable, Inc. of San Diego. Prior to that, she was Vice President of Finance and Administration and Secretary at Websense, Inc. Ms. Carlander joined Websense as Director of Finance and Human Resources during the company’s start-up phase and helped to complete two rounds of funding prior to the company’s March 2000 IPO. Ms. Carlander is a member of the Tech Coast Angels, a 200-member group investing in early-stage biotech and high-tech companies in Southern California. Ms. Carlander received a B.A. in Political Science from the University of California, San Diego, an M.B.A. from San Diego State University, and is a Certified Management Accountant.

Mr. Culley previously served as Director of Business Development & Marketing for Immusol, Inc., a privately-held drug development company in San Diego. At Immusol, Mr. Culley managed all strategic collaborations and licensing agreements. Mr. Culley previously worked in the office of technology transfer at the University of California San Diego and performed drug discovery research at Neurocrine Bioscience, Inc. of San Diego. He received a MS in Biochemistry from the University of California Santa Barbara and an MBA from The Johnson School of Business at Cornell University with an emphasis on private equity and entrepreneurship.

About ADVENTRX
 
ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and viral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information can be found on the Company's website at www.adventrx.com.
 
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration and other regulatory agencies. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.

ADVENTRX Pharmaceuticals
Evan Levine, President and CEO 858-552-0866
or
CEOcast, Inc.
Kevin Theiss, 212-732-4300 


 -----END PRIVACY-ENHANCED MESSAGE-----